Michael Makris/LinkedIn
Jun 18, 2026, 06:43
Michael Makris: Will New Anti-TFPI Drug Armocibat Behaves any Different to Concizumab or Marstacimab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn:
“A Chinese company called Suzhou Alphamab is making an anti-TFPI drug called armocibat, for use in haemophilia with and without inhibitors.
The drug is in phase III at present.
They have just signed a license agreement for a Russian company called Nanolek to produce the drug.
I have no reason to believe that armocibat behaves any different to concizumab or marstacimab, but I hope they have safety surveillance systems to monitor for thrombosis when this drug is no longer in clinical trials.”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering